Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 21Other hematologic neoplasm 3Thoracic 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Classical hematology 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 703Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Lenalidomide 145Granulocyte Colony-Stimulating Factor 145Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 112Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × montanide ISA 51 × Lymphoid × Clear all
NCT03939234 2022-02-21

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Herlev Hospital

Phase 2 Completed
19 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡